Join Prof. Sietze Reitsma for an insightful presentation that will delve into identifying and leveraging key characteristics to optimize patient management and treatment outcomes.

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang discusses how to identify pediatric patients with AD uncontrolled with topical therapies, considerations for the next step in care for these patients, and the potential benefits of early intervention with systemic treatment

Dr. Jason Hawkes discusses the guidelines for chronic spontaneous urticaria and how they will impact patient management.

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.

The infographic provides information about the clinical characteristics used to classify moderate COPD exacerbations and the impact of these events on lung function, future risk, and mortality.

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses about indirect comparison of biologics for CRSwNP, focusing on clinical outcomes like symptom relief and safety and also highlights dupilumab, omalizumab, and mepolizumab as effective and well-tolerated options.
Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.

Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.
Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.